Randy A Vince, Ralph Jiang, Ji Qi, Jeffrey J Tosoian, Rebecca Takele, Felix Y Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C Miller, Arvin George, Khurshid Ghani, Fionna Sun, Mariana Seymore, Robert T Dess, William C Jackson, Matthew Schipper, Daniel E Spratt, Todd M Morgan
BACKGROUND: Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. METHODS: A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database (GRID® ; NCT02609269)...
July 20, 2021: Prostate Cancer and Prostatic Diseases